Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (Rapid Review of TA885)

Matthew James Walton; Mark Rodgers; Helen Athena Fulbright; Alison Jane Eastwood; Robert Hodgson

Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (Rapid Review of TA885)

Matthew James Walton, Mark Rodgers, Helen Athena Fulbright, Alison Jane Eastwood, Robert Hodgson^*

^*Corresponding author for this work

Centre for Reviews and Dissemination

Research output: Book/Report › Commissioned report

Original language	English
Publisher	National Institute for Health and Care Excellence
Commissioning body	National Institute for Health and Care Excellence
Publication status	Published - 13 Dec 2023

Access to Document

https://www.nice.org.uk/guidance/ta939/documents/committee-papers

Cite this

@book{79d87d94ba8344a39336cbc81cb04ab7,

title = "Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (Rapid Review of TA885)",

author = "Walton, {Matthew James} and Mark Rodgers and Fulbright, {Helen Athena} and Eastwood, {Alison Jane} and Robert Hodgson",

year = "2023",

month = dec,

day = "13",

language = "English",

publisher = "National Institute for Health and Care Excellence",

}

TY - BOOK

T1 - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (Rapid Review of TA885)

AU - Walton, Matthew James

AU - Rodgers, Mark

AU - Fulbright, Helen Athena

AU - Eastwood, Alison Jane

AU - Hodgson, Robert

PY - 2023/12/13

Y1 - 2023/12/13

M3 - Commissioned report

BT - Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (Rapid Review of TA885)

PB - National Institute for Health and Care Excellence

ER -